| Authors |
Purohit S, Sharma A, Zhi W, Bai S, Hopkins D, Steed L, Bode B, Anderson SW, Reed
JC, Steed RD, She JX
|
| Submitted By |
Wenbo Zhi on 2/21/2018 |
| Status |
Published |
| Journal |
Frontiers in immunology |
| Year |
2018 |
| Date Published |
|
| Volume : Pages |
9 : 154 |
| PubMed Reference |
29445381 |
| Abstract |
Soluble cytokine receptors may play an important role in development of
microalbuminuria (MA) in type-1 diabetes (T1D). In this study, we measured 12
soluble receptors and ligands from TNF-a/IL6/IL2 pathways in T1D patients with
MA (n?=?89) and T1D patients without MA (n?=?483) participating in the PAGODA
study. Twelve proteins in the sera from T1D patients with and without MA were
measured using multiplex Luminex assays. Ten serum proteins (sTNFR1, sTNFR2,
sIL2Ra, MMP2, sgp130, sVCAM1, sIL6R, SAA, CRP, and sICAM1) were significantly
elevated in T1D patients with MA. After adjusting for age, duration of diabetes,
and sex in logistic regression, association remained significant for seven
proteins. MA is associated with increasing concentrations of all 10 proteins,
with the strongest associations observed for sTNFR1 (OR?=?108.3,P?sTNFR2 (OR?=?65.5,P?(OR?=?5.5,P?sVCAM1 (OR?=?3.3,P?combined odds ratios associated with each quintile for each protein. The risk
scores cluster MA patients into three subsets, each associated with distinct
risk for MA attributable to proteins in the TNF-a/IL6 pathway (mean OR?=?1,
13.5, and 126.3 for the three subsets, respectively). Our results suggest that
the TNF-a/IL6 pathway is overactive in approximately 40% of the MA patients and
moderately elevated in the middle 40% of the MA patients. Our results suggest
the existence of distinct subsets of MA patients identifiable by their serum
protein profiles.
|
|
|